Anti-Inflammatory and Monocyte-Suppressing Effects of Simvastatin in Patients with Impaired Fasting Glucose

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 2, 2011, Pages 131-137

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Ścieszka, Joanna ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFECT; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; ORAL GLUCOSE TOLERANCE TEST; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; FASTING; FEMALE; GLUCOSE; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651427236     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00633.x     Document Type: Article

References (32)

1. Ridker PM, Danielson E, Fonseca FAH, Genes J, Gotto AM, Kastelein JJP et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group. Lancet 1994;344:1383-9.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
5. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009;15:479-89.
6. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203:325-30.
7. Krysiak R, Okopień B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-54.
8. Ukinc K, Ersoz HO, Erem C, Hacihasanoglu AB, Karti SS. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine 2009;35:380-8.
9. Rallidis LS, Hamodraka ES, Fountoulaki K, Moustogiannis G, Zolindaki MG, Kremastinos DT. Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Int J Cardiol 2008;124:271-2.
10. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007;63:113-21.
11. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004;110(Suppl.):S834.
12. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13:123-9.
13. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75.
14. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;2:9-15.
15. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007;186:461-5.
16. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006;91:1770-8.
17. Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007;7:219-24.
18. Kher N, Marsh JD. Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost 2004;30:665-72.
19. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
20. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 2006;98:2P-8P.
21. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007;65(12 Pt 2):S253-9.
22. Vivona N, Bivona G, Noto D, Sasso BL, Cefalù AB, Chiarello G et al. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem 2009;42:1713-8.
23. Okopien B, Kowalski J, Krysiak R, Labuzek K, Stachura-Kulach A, Kulach A et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep 2005;57:367-72.
24. Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2005;45:314-20.
25. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M et al. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 2005;46:377-86.
26. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7(Suppl. 1):328-31.
27. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 2009;7:234-43.
28. Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin 2009;25:431-47.
29. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
31. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;9:3171-82.
32. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007;59:483-99.